

# Taltobulin

**Catalog No: tcsc3299**



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg



## Specifications

**CAS No:**

228266-40-8

**Formula:**

$C_{27}H_{43}N_3O_4$

**Pathway:**

Cell Cycle/DNA Damage;Cytoskeleton;Antibody-drug Conjugate/ADC Related

**Target:**

Microtubule/Tubulin;Microtubule/Tubulin;ADC Cytotoxin

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 100$  mg/mL (211.13 mM)

**Alternative Names:**

HTI-286;SPA-110

**Observed Molecular Weight:**

473.65

## Product Description


Taltobulin (HTI-286; SPA-110) is an analogue of Hemiasterlin; potent tubulin inhibitor; ADCs cytotoxin.

IC50 value:

Target: tubulin

in vitro: HTI-286 significantly inhibited proliferation of all three hepatic tumor cell lines (mean IC50 = 2 nmol/L +/- 1 nmol/L) in vitro. Interestingly, no decrease in viable primary human hepatocytes (PHH) was detected under HTI-286 exposure [1]. In all cell lines tested, HTI-286 was a potent inhibitor of proliferation and induced marked increases in apoptosis. Despite similar transcriptomic changes regarding cell death and cell cycle regulating genes after exposure to HTI-286 or docetaxel, array analysis revealed distinct molecular signatures for both compounds [2].

in vivo: Intravenous administration of HTI-286 significantly inhibited tumor growth in vivo (rat allograft model) [1]. HTI-286 significantly inhibited growth of PC-3 and LNCaP xenografts and retained potency in PC-3dR tumors. Simultaneous castration plus HTI-286 therapy was superior to sequential treatment in the LNCaP model [2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!